Latest News

STAT Plus: FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

The Food and Drug Administration’s surprise decision to reject the company’s Duchenne drug Vyondys 53 on Monday is another twist in the crazy, never-boring Sarepta Therapeutics story.

You can read more about the FDA’s denial of Vyondys 53 here, but read on for some additional thoughts, analyses, and lingering questions for investors trying to figure out what it all means for Sarepta moving forward.

Continue to STAT Plus to read the full story…

Source link

Related posts

The association between partner bereavement and melanoma: cohort studies in the UK and Denmark


Second coronavirus death reported in the US, number of cases 87


Apple touts results from massive AF-detection Apple Watch study


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy